Myeloid-derived suppressor cells and cancer /

Myeloid-derived suppressor cells and cancer /

Saved in:

Bibliographic Details
Author / Creator:	Escors, David, author.
Imprint:	Switzerland : Springer, [2016]
Description:	1 online resource
Language:	English
Series:	SpringerBriefs in immunology SpringerBriefs in immunology.
Subject:	Suppressor cells. T cells. Cancer -- Immunotherapy. Cancer -- Immunotherapy. Suppressor cells. T cells. Electronic books.
Format:	E-Resource Book
URL for this record:	http://pi.lib.uchicago.edu/1001/cat/bib/11253809

Hidden Bibliographic Details
Other authors / contributors:	Talmadge, James E., author. Breckpot, Karine, author. Ginderachter, Jo A. Van, author. Kochan, Grazyna, author.
ISBN:	9783319268217 331926821X 3319268198 9783319268194 9783319268194
Digital file characteristics:	text file PDF
Notes:	Includes bibliographical references. Online resource; title from PDF title page (EBSCO, viewed March 21, 2016).
Summary:	The book starts with an introduction to and history of myeloid-derived suppressor cells (MDSCs), followed by a description of their differentiation, their role in the tumour microenvironment and their therapeutic targeting. It closes with an outlook on future developments. In cancer patients, myelopoiesis is perturbed and instead of generating immunogenic myeloid cells (such as dendritic cells, inflammatory macrophages and granulocytes), there is an increase in highly immature MDSCs. These cells are distributed systemically, resulting in general immunosuppression. They also infiltrate tumours, promoting their progression and metastasis by inhibiting the natural anti-tumour immune response. As these cells also interact with classical anti-neoplastic treatments, they have become major therapeutic targets in the pharmaceutical industry and in oncology research.
Other form:	Printed edition: 9783319268194
Standard no.:	10.1007/978-3-319-26821-7

Description
Summary:	The book starts with an introduction to and history of myeloid-derived suppressor cells (MDSCs), followed by a description of their differentiation, their role in the tumour microenvironment and their therapeutic targeting. It closes with an outlook on future developments. In cancer patients, myelopoiesis is perturbed and instead of generating immunogenic myeloid cells (such as dendritic cells, inflammatory macrophages and granulocytes), there is an increase in highly immature MDSCs. These cells are distributed systemically, resulting in general immunosuppression. They also infiltrate tumours, promoting their progression and metastasis by inhibiting the natural anti-tumour immune response. As these cells also interact with classical anti-neoplastic treatments, they have become major therapeutic targets in the pharmaceutical industry and in oncology research.<br>
Physical Description:	1 online resource
Bibliography:	Includes bibliographical references.
ISBN:	9783319268217 331926821X 3319268198 9783319268194